---
company: Insight Molecular Diagnostics Inc.
ticker: IMDX
form: 8-K
filed: 2026-08-10
accession: 0001493152-26-036863
source: https://www.sec.gov/Archives/edgar/data/1642380/000149315226036863/
---

# Insight Molecular Diagnostics (IMDX) earnings release, August 10, 2026

Insight Molecular Diagnostics Inc. (IMDX) · Form 8-K, Item 2.02 · Filed 2026-08-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1642380/000149315226036863/)

IMDX

Reports

Second Quarter

2026 Results and Timely Progress on FDA Review of GraftAssureDx

NASHVILLE,

TN., August 10, 2026 — Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results:

Fellow shareholders,

We continue to be encouraged by progress toward our most important priority, which is to attain regulatory authorization of GraftAssureDx.

In late July, the FDA completed the current phase of its substantive review of GraftAssureDx in a timely manner. The agency requested additional information from us, which is typical in a regulatory authorization process such as this. We view ourselves as being in the later stages of the review process, and after a thorough dialogue with the agency, we are encouraged to be working with a clear, well-defined set of remaining items. This welcome milestone comes after three years of rigorous kitted product development.

We also have been pleased regarding the agency’s swift engagement and its ability to deliver timely feedback throughout. We have had productive dialogue with the agency since submitting GraftAssureDx for regulatory review in late March, and we expect that to continue.

We would characterize our dialogue with the FDA as routine and within the realm of our expectations.

Our submission was, to our knowledge, the first-ever kitted dd-cfDNA assay to be submitted for FDA authorization.

As a reminder, we are not building this product alone. Our GraftAssure assay runs on a digital PCR instrument made by Bio-Rad Laboratories

(NYSE:BIO), which has invested in our company. Bio-Rad commented:

“Our collaboration with iMDx on GraftAssureDx reflects the kind of innovative thinking we look for in a partner. Droplet Digital

TM

PCR is well suited to the demands of transplant monitoring, where precise and reproducible measurement matters, and GraftAssureDx brings that capability into the clinical laboratory setting. We are proud to partner with iMDx on this program and remain confident in the path forward and positive impact to patient lives.” –Jonathan Seaton, SVP Corporate Business Development, Bio-Rad Laboratories

We also have expanded dialogue with several additional players in the diagnostics industry. We now believe that most major U.S. reference labs are interested in adopting in-house dd-cfDNA testing, with their interest bolstered by reimbursement clarity from Medicare and the release of favorable head-to-head data regarding our assay, both of which are described in more detail below,

High-volume labs that are performing other routine transplant tests are considering the addition of a reimbursed dd-cfDNA test. We believe they may see our test as a natural product line extension for their other transplant test offerings, and as a great way to serve their existing transplant center and nephrology clinic customers nationwide. We believe that these labs value the ability to deliver all the testing needed for a patient in one patient visit for blood draws, and even potentially via one report for clinicians.

Contextual overview for investors: iMDx aims to deliver proven, more affordable, faster tests that can be run in-house at local transplant center laboratories. We have designed the GraftAssureDx molecular test to be sold as a test kit so that transplant center laboratories can run tests locally. By running tests locally, laboratories can deliver critical test results to the physicians of transplant patients much more quickly than can be done with the currently available send-out tests. Our company is now seeking FDA marketing authorization to sell these kits in the U.S. If GraftAssure technology becomes available commercially as a test kit, it may be an industry-transforming event for transplanted organ rejection monitoring.

Over time, iMDx sees three potential paradigm shifts in transplanted organ health monitoring:

Other highlights since our May 2026 update:

Reimbursement and market access

Clinical evidence and peer-reviewed publications

Commercial and scientific community engagement

Upcoming

KOL call on August 17 th to highlight heart transplant testing:

As we continue to plan for commercializing a kitted version of GraftAssure for kidney transplant testing, the next organ of focus for GraftAssure’s application is heart transplant testing. To that end, we will be hosting a virtual key opinion leader (KOL) event to discuss in-house heart transplanted organ rejection testing on Monday, August 17, 2026, at 10:00 a.m. ET. The event will feature Dr. Max Jacob Liebo,

M.D., Associate Professor and Program Director, Advanced Heart Failure and Transplant Cardiology Fellowship at Loyola University Medical

Center.

The call will also feature brief remarks from CEO Josh Riggs and iMDx Vice President of Medical Affairs Dr. Nick Ioannou, whose extensive experience includes previously serving as a medical science liaison for organ health and genetics at Natera.

We will be issuing a separate press release with further information.

Thank you for your interest in iMDx and we look forward to updating you as we transition into commercialization.

Sincerely, iMDx Management

Second

Quarter 2026 financial overview

Webcast and Conference Call Information

Live

Zoom Call and Webcast on August 10, 2026, at 2:00 PMPT / 5:00 PM ET.

Those interested may access the live Zoom call by registering here: iMDx Q2 2026 Earnings Webinar

A replay of the Zoom call will be available on the Company’s website shortly after the call. iMDx

Transplant Products and Product Candidates in Development iMDx’s... (truncated)ell-free DNA (dd-cfDNA). The Company’s scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. iMDx is commercializing this technology using a market-disruptive business strategy.

Under the GraftAssure™ brand, iMDx’s transplant diagnostics include the following:

About

Insight Molecular Diagnostics, Inc.

Insight

Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™,

GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular

Diagnostics Inc.

Forward-Looking

Statements

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,”

“plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the company’s efforts to commercialize its GraftAssure technology, discussions with the FDA and expected FDA marketing authorization to sell GraftAssureDx, the belief that most major U.S. reference labs are interested in adopting in-house dd-cfDNA testing, interest from industry participants and investors, the company’s plans to deliver proven, more affordable and faster tests that can be run in-house at local transplant center laboratories, anticipated paradigm shifts in transplanted organ health monitoring, the belief that clinicians tend to increasingly use dd-cfDNA testing to guide ongoing anti-rejection drug therapy, potential use cases for GraftAssure beyond rejection detection and biopsy rule-out testing, the company’s upcoming KOL call to highlight heart transplant testing, transplant and other product candidates in development, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular

Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

FDA

CAUTION:

This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.

Investor

Contact:

Douglas Farrell

LifeSci Advisors LLC imdx@lifesciadvisors.com

Financial Tables Follow

INSIGHT

## Financial statements

### Income Statement (Three Months Ended June 30, — (In thousands, except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net revenue | 239 | 518 | 271 | 2,656 |
| Cost of revenues | 82 | 180 | 99 | 993 |
| Gross profit | 157 | 338 | 172 | 1,663 |
| Operating expenses: | Research and development | 4,486 | 3,269 | 9,439 | 6,193 |
| Operating expenses: | Sales and marketing | 1,916 | 1,460 | 4,318 | 2,666 |
| Operating expenses: | General and administrative | 2,873 | 2,647 | 5,864 | 5,762 |
| Operating expenses: | Change in fair value of contingent consideration | 2,284 | 2,804 | -3,634 | 3,683 |
| Operating expenses: | Total operating expenses | 11,559 | 10,180 | 15,987 | 18,304 |
| Operating expenses: | Loss from operations | -11,402 | -9,842 | -15,815 | -16,641 |
| Other (expenses) income: | Interest expense | -20 | -25 | -43 | -54 |
| Other (expenses) income: | Other income, net | 162 | 125 | 308 | 282 |
| Other (expenses) income: | Total other income, net | 142 | 100 | 265 | 228 |
| Other (expenses) income: | Loss before income taxes | -11,260 | -9,742 | -15,550 | -16,413 |
| Other (expenses) income: | Net loss | -11,260 | -9,742 | -15,550 | -16,413 |
| Net loss per share: | Net loss per share - basic and diluted | -0.31 | -0.3 | -0.44 | -0.57 |
| Net loss per share: | Weighted average shares outstanding - basic and diluted | 36,750 | 32,023 | 35,640 | 28,876 |

### Income Statement (Three Months Ended — The following is a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measure: (in thousands))

| | Three Months Ended – June 30, – 2026 – (unaudited) | Three Months Ended – March 31, – 2026 – (unaudited) | Three Months Ended – June 30, – 2025 (1) – (unaudited) |
|---|---:|---:|---:|
| Net loss (GAAP) | -11,260 | -4,290 | -9,742 |
| Stock-based compensation | 661 | 615 | 504 |
| Change in fair value of contingent consideration | 2,284 | -5,918 | 2,804 |
| Non-GAAP net loss | -8,315 | -9,593 | -6,434 |
| Depreciation and amortization expenses | 665 | 631 | 559 |
| Interest expense | 20 | 23 | 25 |
| Other income, net | -162 | -146 | -125 |
| Adjusted EBITDA loss, a non-GAAP financial measure | -7,792 | -9,085 | -5,975 |
| Net loss per share (GAAP) | -0.31 | -0.12 | -0.3 |
| Non-GAAP net loss per share | -0.23 | -0.28 | -0.2 |
| Weighted average shares outstanding | 36,750 | 34,519 | 32,023 |

### Balance Sheet (June 30, 2026 — (In thousands) (in thousands))

| | June 30, 2026 – (Unaudited) | December 31, 2025 |
|---|---:|---:|
| CURRENT ASSETS | Cash and cash equivalents | 17,756 | 11,583 |
| CURRENT ASSETS | Accounts receivable, net of allowance for credit losses of $2 and $11, respectively | 192 | 1,128 |
| CURRENT ASSETS | Inventories | 207 | 446 |
| CURRENT ASSETS | Restricted cash, current | 729 | 729 |
| CURRENT ASSETS | Prepaid expenses and other current assets | 1,659 | 1,420 |
| CURRENT ASSETS | Total current assets | 20,543 | 15,306 |
| NONCURRENT ASSETS | Right-of-use operating and financing lease assets, net | 2,097 | 2,815 |
| NONCURRENT ASSETS | Machinery and equipment, net, and construction in progress | 6,004 | 6,435 |
| NONCURRENT ASSETS | Restricted cash, noncurrent | 243 | 607 |
| NONCURRENT ASSETS | Other noncurrent assets | 556 | 593 |
| NONCURRENT ASSETS | TOTAL ASSETS | 29,443 | 25,756 |
| CURRENT LIABILITIES | Accounts payable | 1,871 | 2,544 |
| CURRENT LIABILITIES | Due to related party | 1,979 | 2,780 |
| CURRENT LIABILITIES | Accrued compensation | 1,904 | 2,461 |
| CURRENT LIABILITIES | Accrued royalties | 1,116 | 1,116 |
| CURRENT LIABILITIES | Accrued expenses and other current liabilities | 1,000 | 939 |
| CURRENT LIABILITIES | Operating and financing lease liabilities, current | 1,710 | 1,807 |
| CURRENT LIABILITIES | Contingent consideration liabilities, current | 706 | 428 |
| CURRENT LIABILITIES | Total current liabilities | 10,286 | 12,075 |
| NONCURRENT LIABILITIES | Operating and financing lease liabilities, noncurrent | 915 | 1,690 |
| NONCURRENT LIABILITIES | Contingent consideration liabilities, noncurrent | 39,541 | 43,455 |
| NONCURRENT LIABILITIES | TOTAL LIABILITIES | 50,742 | 57,220 |
| SHAREHOLDERS’ DEFICIT | Common stock, no par value, 230,000 shares authorized; 32,623 and 28,683 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 394,945 | 369,211 |
| SHAREHOLDERS’ DEFICIT | Accumulated other comprehensive income | 67 | 86 |
| SHAREHOLDERS’ DEFICIT | Accumulated deficit | -416,311 | -400,761 |
| SHAREHOLDERS’ DEFICIT | Total shareholders’ deficit | -21,299 | -31,464 |
| SHAREHOLDERS’ DEFICIT | TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | 29,443 | 25,756 |

### Cash Flow (Three Months Ended June 30, — (In thousands) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES: | Net loss | -11,260 | -9,742 | -15,550 | -16,413 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization expense | 665 | 559 | 1,296 | 1,043 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of intangible assets |  |  |  | 7 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation | 661 | 504 | 1,276 | 977 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Equity compensation for bonus awards and consulting services | 8 | 74 | 40 | 88 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Change in fair value of contingent consideration | 2,284 | 2,804 | -3,634 | 3,683 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Unrealized foreign currency losses | 12 | 149 | 7 | 188 |
| Changes in operating assets and liabilities: | Accounts receivable | -35 | 3,028 | 936 | 1,101 |
| Changes in operating assets and liabilities: | Inventories | 175 | -234 | 239 | -283 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | -589 | -168 | -140 | -253 |
